Over €2M subsidy awarded to develop a new miniature glaucoma implant to
PEYEONEER Ophthalmic Solutions,
Medace, Maastricht University and
Maastricht UMC+ .

Glaucoma, the leading cause of irreversible blindness, currently affects more than 80 million people worldwide and is characterized by permanent vision loss eventually resulting in blindness in at least 10% of patients! In order to inhibit progression of the disease, the pressure in the eye must be reduced in many cases. To achieve this, treatment usually begins with medication, but for patients in whom this is not sufficient, surgical procedures are performed. The current surgeries, however, have significant drawbacks, including scarring of the tissue that causes the procedure fails in more than 50% of patients!

A new miniature glaucoma implant has been developed within an international consortium using an innovative biocompatible polymer (SIBS). This implant, easier and faster to implant than conventional implants, has unique properties that lead to better control of eye pressure and less inflammation and scarring. The startup PEYEONEER MedTech was founded to bring this implant to the patient and prevent blindness due to glaucoma.